Avadel Pharmaceuticals (AVDL)
| Bid | 7.97 |
| Market Cap | 791.88M |
| Revenue (ttm) | 169.53M |
| Net Income (ttm) | -48.95M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -16.07 |
| Forward PE | 48.76 |
| Analyst | Buy |
| Ask | 8.49 |
| Volume | 503,431 |
| Avg. Volume (20D) | 1,402,710 |
| Open | 8.49 |
| Previous Close | 8.53 |
| Day's Range | 8.17 - 8.65 |
| 52-Week Range | 7.39 - 19.09 |
| Beta | 1.57 |
About AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorpo...
Analyst Forecast
According to 7 analyst ratings, the average rating for AVDL stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 131.85% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call TranscriptAvadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Austin Murtagh - Precision AQ Gregory Divis - Chief Executive Officer Thomas Mc...
2 months ago · seekingalpha.com
Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 OutlookAvadel Pharmaceuticals' 2025 net sales guidance for Lumryz was significantly below expectations due to increasing patient attrition. The company is increasing efforts to address some of these challeng...